Asia, Australia, North America, South America, Eastern Europe, Western Europe, Middle East, Central America, Africa
Product Description
250mg Faslodex Fulvestrant Solution Injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. 250mg Faslodex Fulvestrant Solution Injection goes through varied quality checks before the final dispatch from our unit.